ARTV
VENTE TOTALE: 85 317 titres (~946 137,86 $ US)
- Insiders
- Aslan Fred
- Total bought
- —
- Total sold
- $946,138
- Last activity
- 2026-09-08
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-10
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | 0.0% | -23304.0% | -82.5% | -1183.0% | -3587.7% | |
| Ebitda Margin | 0.0% | -22335.5% | -75.7% | -1159.5% | -3575.3% | |
| Operating Profit Margin | 0.0% | -26805.6% | -91.6% | -1213.3% | -2660.9% | |
| Pretax Profit Margin | 0.0% | -23304.0% | -82.5% | -1183.0% | -3587.7% | |
| Continuous Operations Profit Margin | 0.0% | -23304.0% | -82.7% | -1184.1% | -3587.7% | |
| Net Profit Margin | 0.0% | -23304.0% | -82.7% | -1184.1% | -3587.7% | |
| Bottom Line Profit Margin | 0.0% | -23304.0% | -82.7% | -1184.1% | -3587.7% | |
| Current Ratio | 8.609 | 15.395 | 6.528 | 4.085 | 8.406 | |
| Quick Ratio | 8.609 | 15.395 | 6.528 | 4.085 | 8.406 | |
| Solvency Ratio | -3.875 | -2.444 | -0.095 | -0.209 | -0.277 | |
| Cash Ratio | 2.040 | 3.284 | 4.376 | 4.001 | 8.336 | |
| Price To Earnings Ratio | -1.251 | -1.938 | -10.084 | -3.614 | -2.941 | |
| Price To Earnings Growth Ratio | 0.037 | -0.006 | 0.157 | 0.194 | -0.010 | |
| Forward Price To Earnings Growth Ratio | 0.037 | -0.006 | 0.157 | 0.194 | -0.010 | |
| Price To Earnings Diluted Ratio | -1.251 | -1.938 | -10.084 | -3.614 | -2.941 | |
| Price To Earnings Diluted Growth Ratio | 0.037 | -0.006 | 0.157 | 0.194 | -0.010 | |
| Price To Book Ratio | 0.954 | 1.316 | -1.724 | -1.500 | -2.375 | |
| Price To Sales Ratio | 0.000 | 978.407 | 8.342 | 42.790 | 105.394 | |
| Price To Free Cash Flow Ratio | -1.322 | -4.411 | -5.512 | -3.693 | -12.391 | |
| Price To Operating Cash Flow Ratio | -1.366 | -4.462 | -5.890 | -4.151 | -13.787 | |
| Debt To Assets Ratio | 0.084 | 0.068 | 0.161 | 0.146 | 0.010 | |
| Debt To Equity Ratio | 0.099 | 0.077 | -0.104 | -0.138 | -0.020 | |
| Debt To Capital Ratio | 0.090 | 0.071 | -0.117 | -0.160 | -0.020 | |
| Long Term Debt To Capital Ratio | 0.067 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.191 | 1.123 | -0.649 | -0.946 | -1.912 | |
| Working Capital Turnover Ratio | 0.000 | 0.002 | 0.457 | 0.044 | 0.025 | |
| Operating Cash Flow Ratio | -5.865 | -4.491 | -3.879 | -1.984 | -0.793 | |
| Operating Cash Flow Sales Ratio | 0.000 | -219.251 | -1.416 | -10.308 | -7.644 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.034 | 1.012 | 1.069 | 1.124 | 1.113 | |
| Debt Service Coverage Ratio | -26.567 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -25.090 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -7.014 | -3.834 | -2.805 | -2.614 | -8.790 | |
| Capital Expenditure Coverage Ratio | -29.668 | -85.720 | -14.558 | -8.069 | -8.877 | |
| Dividend Paid And Capex Coverage Ratio | -29.668 | -85.720 | -14.558 | -8.069 | -8.877 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.096 | -3.919 | -9.574 | -2.237 | -0.724 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | ▼-100.0% | ▼-80.0% |
| Ebit Margin | 0.0% | ▲23304.0% | ▲5631.4% |
| Ebitda Margin | 0.0% | ▲22335.5% | ▲5429.2% |
| Operating Profit Margin | 0.0% | ▲26805.6% | ▲6154.3% |
| Pretax Profit Margin | 0.0% | ▲23304.0% | ▲5631.4% |
| Continuous Operations Profit Margin | 0.0% | ▲23304.0% | ▲5631.7% |
| Net Profit Margin | 0.0% | ▲23304.0% | ▲5631.7% |
| Bottom Line Profit Margin | 0.0% | ▲23304.0% | ▲5631.7% |
| Current Ratio | 8.609 | ▼-6.786 | ▲0.004 |
| Quick Ratio | 8.609 | ▼-6.786 | ▲0.004 |
| Solvency Ratio | -3.875 | ▼-1.432 | ▼-2.495 |
| Cash Ratio | 2.040 | ▼-1.243 | ▼-2.367 |
| Price To Earnings Ratio | -1.251 | ▲0.688 | ▲2.715 |
| Price To Earnings Growth Ratio | 0.037 | ▲0.043 | ▼-0.038 |
| Forward Price To Earnings Growth Ratio | 0.037 | ▲0.043 | ▼-0.038 |
| Price To Earnings Diluted Ratio | -1.251 | ▲0.688 | ▲2.715 |
| Price To Earnings Diluted Growth Ratio | 0.037 | ▲0.043 | ▼-0.038 |
| Price To Book Ratio | 0.954 | ▼-0.362 | ▲1.619 |
| Price To Sales Ratio | 0.000 | ▼-978.407 | ▼-226.987 |
| Price To Free Cash Flow Ratio | -1.322 | ▲3.089 | ▲4.144 |
| Price To Operating Cash Flow Ratio | -1.366 | ▲3.096 | ▲4.565 |
| Debt To Assets Ratio | 0.084 | ▲0.015 | ▼-0.010 |
| Debt To Equity Ratio | 0.100 | ▲0.023 | ▲0.117 |
| Debt To Capital Ratio | 0.090 | ▲0.019 | ▲0.117 |
| Long Term Debt To Capital Ratio | 0.067 | ▲0.067 | ▲0.053 |
| Financial Leverage Ratio | 1.191 | ▲0.068 | ▲1.429 |
| Working Capital Turnover Ratio | 0.000 | ▼-0.002 | ▼-0.106 |
| Operating Cash Flow Ratio | -5.865 | ▼-1.373 | ▼-2.462 |
| Operating Cash Flow Sales Ratio | 0.000 | ▲219.251 | ▲47.724 |
| Free Cash Flow Operating Cash Flow Ratio | 1.034 | ▲0.022 | ▼-0.036 |
| Debt Service Coverage Ratio | -26.567 | ▼-26.567 | ▼-21.253 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -25.090 | ▼-25.090 | ▼-20.072 |
| Operating Cash Flow Coverage Ratio | -7.014 | ▼-3.180 | ▼-2.003 |
| Capital Expenditure Coverage Ratio | -29.668 | ▲56.052 | ▼-0.290 |
| Dividend Paid And Capex Coverage Ratio | -29.668 | ▲56.052 | ▼-0.290 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.096 | ▲2.822 | ▲2.414 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $104.9M | $245.6M | $279.4M | $211.0M | $211.0M | |
| Enterprise value | $89.1M | $219.7M | $242.8M | $127.9M | $51.8M | |
| EV / Sales | 0.00x | 875.30x | 7.25x | 25.94x | 25.88x | |
| EV / Op. cash flow | -1.16x | -3.99x | -5.12x | -2.52x | -3.39x | |
| EV / Free cash flow | -1.12x | -3.95x | -4.79x | -2.24x | -3.04x | |
| EV / EBITDA | -1.10x | -3.92x | -9.57x | -2.24x | -0.72x | |
| Net debt / EBITDA | 0.19x | 0.46x | 1.44x | 1.45x | 2.22x | |
| Current ratio | 8.61x | 15.39x | 6.53x | 4.08x | 8.41x | |
| Income quality | 0.92x | 0.84x | 1.65x | 0.86x | 0.21x | |
| Graham net-net | $4 | $7 | -$8 | -$10 | -$6 | |
| Tax burden | 100.0% | 100.0% | 100.3% | 100.1% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $99.6M | $176.4M | $67.6M | $79.0M | $143.0M | |
| Invested capital | $116.9M | $196.8M | $92.2M | $106.7M | $147.1M | |
| Return on assets | -64.0% | -27.9% | -26.3% | -43.9% | -42.3% | |
| Operating ROA | -53.2% | -42.8% | -25.8% | -39.5% | -53.5% | |
| Return on tangible assets | -64.0% | -27.9% | -26.3% | -43.9% | -42.3% | |
| Return on equity | -76.3% | -31.3% | 17.1% | 41.5% | 80.8% | |
| Return on invested capital | -74.9% | -33.5% | -31.8% | -53.9% | -35.3% | |
| Return on capital employed | -76.9% | -34.1% | -33.0% | -55.7% | -35.4% | |
| Earnings yield | -80.0% | -23.8% | -9.9% | -27.7% | -34.0% | |
| Free cash flow yield | -75.7% | -22.7% | -18.1% | -27.1% | -8.1% | |
| Capex / Op. cash flow | -3.4% | -1.2% | -6.9% | -12.4% | -11.3% | |
| Capex / Depreciation | 99.6% | 26.4% | 143.8% | 544.0% | 695.2% | |
| Capex / Sales | 0.0% | 255.8% | 9.7% | 127.7% | 86.1% | |
| SG&A / Sales | 0.0% | 6854.6% | 41.5% | 421.3% | 642.6% | |
| R&D / Sales | 0.0% | 20051.0% | 150.0% | 892.0% | 2118.4% | |
| Stock comp / Sales | 0.0% | 2780.9% | 21.1% | 133.5% | 215.1% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 212d | 19d | 39d | 85d | |
| Days payables outstanding | 50d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 212d | 19d | 39d | 85d | |
| Cash conversion cycle | -50d | 212d | 19d | 39d | 85d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-57.3%EV / Sales ▼-100.0%EV / EBITDA ▲+72.0%EV / Op. cash flow ▲+2.831Earnings yield ▼-0.562
Profitability
Return on equity ▼-0.449Return on assets ▼-0.361Return on invested capital ▼-0.415Return on capital employed ▼-0.428Operating ROA ▼-0.105Income quality ▲+0.073Tax burden 0.000
Efficiency
Days sales outstanding ▼-212.311Days payables outstanding n/aOperating cycle ▼-212.311Cash conversion cycle ▼-262.205Capex / Sales ▼-2.558R&D / Sales ▼-200.510
Balance-sheet strength
Current ratio ▼-6.786Net debt / EBITDA ▼-0.268Working capital ▼-76799000.000Invested capital ▼-79869000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-50.3%EV / Sales ▼-100.0%EV / EBITDA ▼-51.5%EV / Op. cash flow ▲+2.225Earnings yield ▼-0.459
Profitability
Return on equity ▼-1.571Return on assets ▼-0.218Return on invested capital ▼-0.397Return on capital employed ▼-0.415Operating ROA ▲+0.003Income quality ▲+0.702Tax burden 0.000
Efficiency
Days sales outstanding ▼-85.325Days payables outstanding n/aOperating cycle ▼-85.325Cash conversion cycle ▼-135.219Capex / Sales ▼-0.861R&D / Sales ▼-21.184
Balance-sheet strength
Current ratio ▲+0.203Net debt / EBITDA ▼-2.030Working capital ▼-43403000.000Invested capital ▼-30126000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-08 Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2a basket trial, each with at least six months of follow-up, including at least 10 patients who would meet key eligibility criteria for the Phase 3 registrational trial in refractory RA Updated clinical data expected in the second half of 2026 from at least 10 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc), each with at least six months of follow-up Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK® plus rituximab versus rituximab alone in approximately 150 patients with refractory RA, with further updates on site activation and enrollment initiation expected in the second half of 2026 SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today provided an update on anticipated data disclosures and development milestones for its lead program, AlloNK® (also known as AB-101), through year-end 2026.
- 2026-09-02 Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate at the following investor conferences: 2026 Cantor Global Healthcare Conference – live fireside chat on Wednesday, September 9, 2026 at 10:20 am EDT H.C.
- 2026-08-26 2,353,304 Shares in Artiva Biotherapeutics, Inc. $ARTV Acquired by 5AM Venture Management LLC 5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 2,353,304 shares of the company''s stock, valued at approximately $22,827,049,000. Artiva Biotherapeutics accounts for 7.9% of 5AM
- 2026-08-11 Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR) ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Valuation and Earnings This table compares ProQR
- 2026-08-06 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®''s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient administration U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory rheumatoid arthritis (RA) Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients in the second half of 2026 Strong balance sheet with cash, cash equivalents and investments of $349.4 million as of June 30, 2026, expected to fund operations into 2029 SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced financial results for the second quarter ended June 30, 2026, and highlighted recent progress. “The second quarter was transformative for Artiva.
- 2026-07-17 Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the “Inducement Grants”) for 17 new employees.
- 2026-07-08 Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.
- 2026-06-23 Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 3:30 pm EDT.